Researcher Verification

Vayron Labs sells research compounds exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.

I am at least 21 years of age.

I confirm I am a qualified researcher purchasing for in vitro / laboratory research only — not for human or veterinary use.

By proceeding you affirm the statements above are true. Products are not for human or veterinary use, not for use in diagnostic procedures, and have not been evaluated by the U.S. Food and Drug Administration. Full disclaimer.

Ara-290

$54.95

ARA-290 (Cibinetide) is an experimental synthetic peptide derived from the structure of erythropoietin (EPO), a naturally occurring hormone involved in red blood cell production. Unlike conventional EPO, ARA-290 was developed to investigate tissue-protective and anti-inflammatory signaling pathways without stimulating red blood cell production. It has attracted research interest in nerve health, cellular protection, inflammatory signaling, and tissue-repair mechanisms.

Guaranteed Safe Checkout

ARA-290, also known as Cibinetide, is an 11-amino-acid synthetic peptide modeled after a specific region of erythropoietin (EPO). It was designed to investigate the tissue-protective properties associated with EPO while avoiding its conventional effects on red blood cell production.

ARA-290 has been studied for its interaction with the proposed innate repair receptor (IRR), a signaling pathway associated with cellular protection, inflammatory regulation, and tissue responses to injury. Its unique research profile has generated interest in neurological research, small-fiber nerve function, and cellular recovery.
PHL Academy+1

Where the interest is
– Nerve health research: Clinical studies have investigated ARA-290 in relation to small-fiber neuropathy, particularly nerve-related symptoms associated with sarcoidosis.
– Inflammatory signaling: Research focuses on its potential influence on inflammatory pathways and cellular responses to tissue stress.
– Tissue protection: Researchers are investigating its relationship with cellular survival, tissue integrity, and protective mechanisms involving the proposed innate repair receptor.
What to expect

ARA-290 is an investigational research peptide with some early human clinical research, including small Phase II studies. These studies have explored its potential effects on small-fiber neuropathy and related neurological measurements. However, the available evidence remains limited, and larger independent clinical trials are needed to establish its effectiveness and safety.
Peptide Evidence Registry+2

Although early findings have generated scientific interest, ARA-290 is not an approved medicine for routine clinical use. Its long-term safety, appropriate clinical applications, and effectiveness across different conditions remain insufficiently established. Research involving ARA-290 should not be interpreted as a guarantee of therapeutic benefits or as a replacement for approved medical care.

Research use only. Not for human or veterinary use.